| Oct 1 |
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
|
| Sep 24 |
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
|
| Sep 19 |
Cybin Provides Corporate Update on Upcoming Clinical Milestones
|
| Sep 19 |
'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale
|
| Sep 19 |
Cybin Announces Completion of Previously Announced Share Consolidation
|
| Sep 15 |
Wall Street Breakfast: The Week Ahead
|
| Sep 4 |
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 27 |
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
|
| Aug 13 |
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
|
| Aug 12 |
Medical journal retracts three articles related to MDMA for PTSD
|
